Cortexyme presents new data demonstrating atuzaginstat disrupts biofilms and is efficacious in preclinical models of periodontal disease at iadr 2021

South san francisco, calif.--(business wire)---- $crtx--cortexyme, inc. (nasdaq: crtx), a company advancing a pivotal trial in alzheimer's disease with top-line data expected in the fourth quarter of 2021 and a growing pipeline of therapeutics for degenerative diseases, announced new preclinical data demonstrating efficacious dose range finding data for its lead drug candidate atuzaginstat (cor388) in periodontal disease in conjunction with its participation at the international association for dental re
QNCX Ratings Summary
QNCX Quant Ranking